{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:21:57Z","timestamp":1783952517786,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02725-1","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:55:02Z","timestamp":1781247302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Liposomal doxorubicin plus nab-paclitaxel with\/without chemoradiotherapy in head and neck adenoid cystic carcinoma: single-arm phase II study"],"prefix":"10.1038","volume":"11","author":[{"given":"Xinxin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"2725_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2021.105213","volume":"115","author":"L Lorini","year":"2021","unstructured":"Lorini, L. et al. Prognosis and management of recurrent and\/or metastatic head and neck adenoid cystic carcinoma. Oral. Oncol. 115, 105213 (2021).","journal-title":"Oral. Oncol."},{"key":"2725_CR2","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.21873\/anticanres.16929","volume":"44","author":"M Zupancic","year":"2024","unstructured":"Zupancic, M., N\u00e4sman, A., Friesland, S. & Dalianis, T. Adenoid cystic carcinoma, clinical presentation, current treatment and approaches toward novel therapies. Anticancer Res. 44, 1325\u20131334 (2024).","journal-title":"Anticancer Res."},{"key":"2725_CR3","doi-asserted-by":"publisher","first-page":"188523","DOI":"10.1016\/j.bbcan.2021.188523","volume":"1875","author":"J Nightingale","year":"2021","unstructured":"Nightingale, J., Lum, B., Ladwa, R., Simpson, F. & Panizza, B. Adenoid cystic carcinoma: a review of clinical features, treatment targets and advances in improving the immune response to monoclonal antibody therapy. Biochim. Biophys. Acta Rev. Cancer 1875, 188523 (2021).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"2725_CR4","doi-asserted-by":"crossref","unstructured":"Dewenter, I., Otto, S., Kakoschke, T. K., Smolka, W. & Obermeier, K. T. Recent advances, systemic therapy, and molecular targets in adenoid cystic carcinoma of the head and neck. J. Clin. Med. 12, 1463 (2023).","DOI":"10.3390\/jcm12041463"},{"key":"2725_CR5","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1200\/JCO.22.02221","volume":"41","author":"R Ferrarotto","year":"2023","unstructured":"Ferrarotto, R. et al. Phase II clinical trial of axitinib and avelumab in patients with recurrent\/metastatic adenoid cystic carcinoma. J. Clin. Oncol. 41, 2843\u20132851 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2725_CR6","doi-asserted-by":"publisher","first-page":"321","DOI":"10.46883\/ONC.3408.321","volume":"34","author":"S Darabi","year":"2020","unstructured":"Darabi, S., Braxton, D. R., Eisenberg, B. L. & Demeure, M. J. Predictive biomarkers for immunotherapy response beyond PD-1\/PD-L1. Oncology 34, 321\u2013327 (2020).","journal-title":"Oncology"},{"key":"2725_CR7","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1158\/1078-0432.CCR-19-2214","volume":"26","author":"CP Rodriguez","year":"2020","unstructured":"Rodriguez, C. P. et al. A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer. Clin. Cancer Res. 26, 837\u2013845 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2725_CR8","doi-asserted-by":"publisher","first-page":"6084","DOI":"10.1200\/JCO.2019.37.15_suppl.6084","volume":"37","author":"V Tchekmedyian","year":"2019","unstructured":"Tchekmedyian, V. et al. A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent\/metastatic adenoid cystic carcinoma (R\/M ACC). J. Clin. Oncol. 37, 6084\u20136084 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2725_CR9","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1038\/s41591-023-02518-x","volume":"29","author":"JL Vos","year":"2023","unstructured":"Vos, J. L. et al. Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial. Nat. Med. 29, 3077\u20133089 (2023).","journal-title":"Nat. Med."},{"key":"2725_CR10","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1200\/JCO.18.01859","volume":"37","author":"V Tchekmedyian","year":"2019","unstructured":"Tchekmedyian, V. et al. Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma. J. Clin. Oncol. 37, 1529\u20131537 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2725_CR11","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.21037\/tcr-21-2433","volume":"11","author":"N Su","year":"2022","unstructured":"Su, N. et al. Efficacy and safety of anlotinib in metastatic adenoid cystic carcinoma: a retrospective study. Transl. Cancer Res. 11, 2757\u20132766 (2022).","journal-title":"Transl. Cancer Res."},{"key":"2725_CR12","doi-asserted-by":"publisher","first-page":"175883592110136","DOI":"10.1177\/17588359211013626","volume":"13","author":"G Zhu","year":"2021","unstructured":"Zhu, G. et al. Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a single-arm, phase II prospective study. Ther. Adv. Med. Oncol. 13, 17588359211013626 (2021).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"2725_CR13","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/hed.23925","volume":"38","author":"PM Dillon","year":"2016","unstructured":"Dillon, P. M., Chakraborty, S., Moskaluk, C. A., Joshi, P. J. & Thomas, C. Y. Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials. Head Neck 38, 620\u2013627 (2016).","journal-title":"Head Neck"},{"key":"2725_CR14","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S1470-2045(10)70245-X","volume":"12","author":"SA Laurie","year":"2011","unstructured":"Laurie, S. A., Ho, A. L., Fury, M. G., Sherman, E. & Pfister, D. G. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol. 12, 815\u2013824 (2011).","journal-title":"Lancet Oncol."},{"key":"2725_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jconrel.2012.05.045","volume":"164","author":"F Kratz","year":"2012","unstructured":"Kratz, F. & Warnecke, A. Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nanosized drug delivery systems. J. Control. Release 164, 221\u2013235 (2012).","journal-title":"J. Control. Release"},{"key":"2725_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.drup.2016.10.003","volume":"29","author":"AA Gabizon","year":"2016","unstructured":"Gabizon, A. A., Patil, Y. & La-Beck, N. M. New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. Drug Resist. Updates 29, 90\u2013106 (2016).","journal-title":"Drug Resist. Updates"},{"key":"2725_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41392-023-01536-y","volume":"8","author":"D Fan","year":"2023","unstructured":"Fan, D. et al. Nanomedicine in cancer therapy. Signal Transduct. Target. Ther. 8, 293 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2725_CR18","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1021\/acs.molpharmaceut.1c00046","volume":"18","author":"A Spada","year":"2021","unstructured":"Spada, A., Emami, J., Tuszynski, J. A. & Lavasanifar, A. The uniqueness of albumin as a carrier in nanodrug delivery. Mol. Pharm. 18, 1862\u20131894 (2021).","journal-title":"Mol. Pharm."},{"key":"2725_CR19","doi-asserted-by":"publisher","first-page":"120117","DOI":"10.1016\/j.ijpharm.2020.120117","volume":"593","author":"V Makwana","year":"2021","unstructured":"Makwana, V., Karanjia, J., Haselhorst, T., Anoopkumar-Dukie, S. & Rudrawar, S. Liposomal doxorubicin as targeted delivery platform: current trends in surface functionalization. Int. J. Pharm. 593, 120117 (2021).","journal-title":"Int. J. Pharm."},{"key":"2725_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.52679\/tabcj.2021.0010","volume":"2","author":"R Hossain","year":"2021","unstructured":"Hossain, R. et al. Doxorubicin hydrochloride liposome and albumin-bound paclitaxel in cancer: a nanotechnology perspective. Appl. Biol. Chem. J. 2, 59\u201365 (2021).","journal-title":"Appl. Biol. Chem. J."},{"key":"2725_CR21","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.2217\/fon-2019-0742","volume":"16","author":"A Fabi","year":"2020","unstructured":"Fabi, A. et al. Nanoparticle albumin-bound paclitaxel\/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients. Future Oncol. 16, 1629\u20131637 (2020).","journal-title":"Future Oncol."},{"key":"2725_CR22","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/oxfordjournals.annonc.a058665","volume":"4","author":"JB Vermorken","year":"1993","unstructured":"Vermorken, J. B. et al. Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. Ann. Oncol. 4, 785\u2013788 (1993).","journal-title":"Ann. Oncol."},{"key":"2725_CR23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/hed.20327","volume":"28","author":"J Gilbert","year":"2006","unstructured":"Gilbert, J. et al. Phase II trial of Taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck 28, 197\u2013204 (2006).","journal-title":"Head Neck"},{"key":"2725_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1053\/svms.2003.36617","volume":"18","author":"JA McKnight","year":"2003","unstructured":"McKnight, J. A. Principles of chemotherapy. Clin. Tech. Small Anim. Pract. 18, 67\u201372 (2003).","journal-title":"Clin. Tech. Small Anim. Pract."},{"key":"2725_CR25","doi-asserted-by":"crossref","unstructured":"Sun, Y., Liu, Y., Ma, X. & Hu, H. The influence of cell cycle regulation on chemotherapy. Int. J. Mol. Sci. 22, 6923 (2021).","DOI":"10.3390\/ijms22136923"},{"key":"2725_CR26","unstructured":"China Anti-Cancer Association. Core Popular Science Knowledge on Cancer Prevention and Treatment in China. http:\/\/www.caca.org.cn\/kpxc\/2024hxzs\/index.shtml."},{"key":"2725_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/sj.bjc.6604444","volume":"99","author":"SA Bhide","year":"2008","unstructured":"Bhide, S. A. et al. Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer. Br. J. Cancer 99, 57\u201362 (2008).","journal-title":"Br. J. Cancer"},{"key":"2725_CR28","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/archotol.1981.00790480015004","volume":"107","author":"VL Schramm Jr","year":"1981","unstructured":"Schramm, V. L. Jr, Srodes, C. & Myers, E. N. Cisplatin therapy for adenoid cystic carcinoma. Arch. Otolaryngol. 107, 739\u2013741 (1981).","journal-title":"Arch. Otolaryngol."},{"key":"2725_CR29","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/1097-0142(20010201)91:3<541::AID-CNCR1032>3.0.CO;2-Y","volume":"91","author":"M Airoldi","year":"2001","unstructured":"Airoldi, M. et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 91, 541\u2013547 (2001).","journal-title":"Cancer"},{"key":"2725_CR30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/COC.0000000000000112","volume":"40","author":"M Airoldi","year":"2017","unstructured":"Airoldi, M. et al. Cisplatin+vinorelbine treatment of recurrent or metastatic salivary gland malignancies (RMSGM): a final report on 60 cases. Am. J. Clin. Oncol. 40, 86\u201390 (2017).","journal-title":"Am. J. Clin. Oncol."},{"key":"2725_CR31","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1158\/1078-0432.CCR-16-2942","volume":"23","author":"PM Dillon","year":"2017","unstructured":"Dillon, P. M. et al. A phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma. Clin. Cancer Res. 23, 4138\u20134145 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2725_CR32","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1002\/cncr.29401","volume":"121","author":"B Keam","year":"2015","unstructured":"Keam, B. et al. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer 121, 2612\u20132617 (2015).","journal-title":"Cancer"},{"key":"2725_CR33","doi-asserted-by":"publisher","first-page":"103677","DOI":"10.1016\/j.critrevonc.2022.103677","volume":"174","author":"MS Al-Zoubi","year":"2022","unstructured":"Al-Zoubi, M. S. & Al-Zoubi, R. M. Nanomedicine tactics in cancer treatment: challenge and hope. Crit. Rev. Oncol. Hematol. 174, 103677 (2022).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2725_CR34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4155\/tde.12.147","volume":"4","author":"SM Miller","year":"2013","unstructured":"Miller, S. M. & Wang, A. Z. Nanomedicine in chemoradiation. Ther. Deliv. 4, 239\u2013250 (2013).","journal-title":"Ther. Deliv."},{"key":"2725_CR35","doi-asserted-by":"crossref","unstructured":"Ramos, A., Sadeghi, S. & Tabatabaeian, H. Battling chemoresistance in cancer: root causes and strategies to uproot them. Int. J. Mol. Sci. 22, 9451 (2021).","DOI":"10.3390\/ijms22179451"},{"key":"2725_CR36","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/264542a0","volume":"264","author":"L Norton","year":"1976","unstructured":"Norton, L., Simon, R., Brereton, H. D. & Bogden, A. E. Predicting the course of Gompertzian growth. Nature 264, 542\u2013545 (1976).","journal-title":"Nature"},{"key":"2725_CR37","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semcancer.2019.08.019","volume":"60","author":"C D\u2019Alterio","year":"2020","unstructured":"D\u2019Alterio, C., Scala, S., Sozzi, G., Roz, L. & Bertolini, G. Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion. Semin. Cancer Biol. 60, 351\u2013361 (2020).","journal-title":"Semin. Cancer Biol."},{"key":"2725_CR38","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan, N., Baselga, J. & Hyman, D. M. A view on drug resistance in cancer. Nature 575, 299\u2013309 (2019).","journal-title":"Nature"},{"key":"2725_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack, I. & Shaw, A. T. Tumor heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15, 81\u201394 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2725_CR40","doi-asserted-by":"crossref","unstructured":"Aloss, K. & Hamar, P. Recent preclinical and clinical progress in liposomal doxorubicin. Pharmaceutics 15, 893 (2023).","DOI":"10.3390\/pharmaceutics15030893"},{"key":"2725_CR41","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.2147\/DDDT.S88023","volume":"9","author":"MN Kundranda","year":"2015","unstructured":"Kundranda, M. N. & Niu, J. Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Des. Dev. Ther. 9, 3767\u20133777 (2015).","journal-title":"Drug Des. Dev. Ther."},{"key":"2725_CR42","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1093\/annonc\/mds172","volume":"23","author":"CF Verschraegen","year":"2012","unstructured":"Verschraegen, C. F. et al. Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer. Ann. Oncol. 23, 3104\u20133110 (2012).","journal-title":"Ann. Oncol."},{"key":"2725_CR43","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520944310","volume":"48","author":"L Wang","year":"2020","unstructured":"Wang, L. et al. Combination of pegylated liposomal doxorubicin and docetaxel as neoadjuvant therapy for breast cancer with axillary lymph node metastasis. J. Int. Med. Res. 48, 0300060520944310 (2020).","journal-title":"J. Int. Med. Res."},{"key":"2725_CR44","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1001\/jamaoncol.2022.5985","volume":"9","author":"S Agrawal","year":"2023","unstructured":"Agrawal, S. et al. Use of single-arm trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021. JAMA Oncol. 9, 266\u2013272 (2023).","journal-title":"JAMA Oncol."},{"key":"2725_CR45","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/oxfordjournals.annonc.a010684","volume":"7","author":"L Licitra","year":"1996","unstructured":"Licitra, L. et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann. Oncol. 7, 640\u2013642 (1996).","journal-title":"Ann. Oncol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02725-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02725-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02725-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:02:23Z","timestamp":1783951343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02725-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2725"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02725-1","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The sentence \"The 1-year and 2-year OS rates were....\" was corrected.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"230"}}